A Phase 1 interventional study of Peripheral Nerve Stimulation and Lidocaine IV in Anesthesia and Pain, sponsored by Keith M Vogt. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-24.
Sponsored by Keith M Vogt · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 204 studies testing lidocaine in Pain — 19 open to participants now, 19 under way, 1 of them phase 3. Lidocaine · Pain.
Among the 204 studies testing lidocaine in Pain, this one is the 160th largest by enrollment of the 203 interventional ones that give a count, is one of 6 that started in 2022, is one of 8 in phase 1, and was the 169th registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →19 of the 204 studies testing lidocaine in Pain are open now, in 9 countries. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Northwell Health · Sites in United States
Ages 18+ · Women only
Montefiore Medical Center · Sites in United States
Ages 18–50 · Women only
Cairo University · Sites in Egypt
Ages 18–65 · Healthy volunteers
Ain Shams University · Sites in Egypt
Ages 18–40 · Women only
By country, each count listing its studies:
Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
204 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 32 · Phase 3 34 · Phase 4 63
First in 2002; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 66 across the 203 interventional studies. Of the 157 that completed or were terminated, 66 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 204 have an industry lead sponsor. The 10 most frequent:
Keith M Vogt is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Keith M Vogt has 6 studies filed under Pain — fewer than ten, so there is no comparison to draw.
5 of the studies testing lidocaine in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07785674Mayo ClinicArm Elevation for Prevention of Propofol Injection Pain | 2027-01 |
| NCT07883473Shaheed Zulfiqar Ali Bhutto Medical UniversityPudendal Nerve Block for Pain Relief During Episiotomy Repair | 2027-01-31 |
| NCT07889687Northwell HealthThis Study is Comparing Pain Outcomes After Urethral Bulking When Participants Are Randomized to Two Different Pain Medication Regimens. | 2027-04 |
| NCT07546370Monakshi SawhneyThe Effectiveness of Topical Prilocaine-Lidocaine Cream Plus Acetaminophen and Naproxen Compared to Lidocaine Injection Plus Acetaminophen and Naproxen to Manage Pain During IntraUterine Device Insertion | 2027-04-14 |
| NCT07048769Montefiore Medical CenterParacervical Block for Pain Reduction in Saline Infusion Sonograms | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 204 studies testing lidocaine in Pain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize the effects of intravenous lidocaine on pain processing and cognitive function. Functional magnetic resonance imaging will be used to identify the neural correlates of these phenomena. The study will consist of 1 visit and involves no long-term follow up.
This is an observational cohort study of volunteer subjects, which will employ neuroimaging and behavioral measures to characterize the effects of intravenous lidocaine on pain processing and cognitive function. A steady-state effect-site concentration of lidocaine will be achieved, and a short battery of cognitive behavioral tasks will be employed. At the dose target, pain task functional MRI and resting-state connectivity will be determined. This work will use a systems neuroscience approach to fill an important knowledge gap about the central effects of intravenous lidocaine, a commonly-used opioid alternative analgesic agent.
Aim1: Determine cognitive behavioral effects of a steady-state dose of IV lidocaine using a short battery of tasks. The investigators hypothesize that the administration of lidocaine will correlate to decreased pain ratings, slowed psychomotor response, and decreased memory encoding.
Aim2: Determine the neural effects of a steady-state dose of IV lidocaine in response to acute pain, and on resting connectivity. The investigators hypothesize that pain task-related activation will decrease in the insula and anterior cingulate, corresponding to decreased ratings of pain intensity and unpleasantness. Additionally, the investigators expect widespread decreases in long-range functional connectivity between brain areas know to be involved in these two areas and other known to be involved in pain processing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive lidocaine during the drug portion of the experiment.
Device: Peripheral Nerve Stimulation · Drug: Lidocaine IV
Experimental acute pain stimulus will be delivered using an electric nerve stimulator.
Also known as: Electric Nerve Stimulation
Subjects will receive an intravenous infusion of lidocaine for about 30 minutes.
Also known as: Xylocaine
Brain Activation to Painful Stimulation Difference: Drug-free Condition Minus Lidocaine Condition
The Z-score is calculated by linear regression of the task timing against the MRI signal time-course (MRI data is in arbitrary units with no maximum or minimum) at each voxel (single data point in brain). Primary outcome is listed for the Right insula, but similar scores are calculated throughout the brain. Z-score of 0 indicates no task-related changes. Z-scores further from zero indicate stronger correlation between functional MRI signal change and the task timing, with positive values indicating increases in fMRI signal and negative Z-scores indicating decreases. Practically, higher positive Z-scores indicate increased brain activity and larger negative Z-scores indicate decreased brain activity. This outcome is reported as a number, as it is calculated using all the data across subjects combined into one statistical measure for the overall strength of difference in MRI signal change between two groups of data. Dispersion measures cannot be calculated for the summary Z-score.
Time frame: 4.5 minutes
Resting-state Functional Connectivity Difference: Drug-free Minus Lidocaine
Functional connectivity (FC) measures the correlation of MRI signal time-series between brain regions. Changes in FC reflect differences in brain state, in this case between drug-free and lidocaine conditions. The reported value is the FC change between the right insula and anterior cingulate. A T-statistic of 0 indicates no change; more positive scores mean stronger connectivity in the drug-free condition, and more negative scores mean stronger connectivity with lidocaine. This outcome is a number reflecting the overall magnitude of difference between two datasets, calculated in one summary statistic. Dispersion measures cannot be calculated for the T-statistic in this analysis framework.
Time frame: 8 minutes
Pain Intensity Score Difference, Drug-free Condition Minus Lidocaine Condition
Numerical rating scale (0-10) pain score difference, comparing drug-free to the steady-state dose of lidocaine. Higher pain scores indicate more pain; a positive difference between pain score during the drug-free condition minus the value during the lidocaine condition indicates pain reduction (a better outcome).
Time frame: 12 minutes
Memory Performance Difference, Drug-free Minus Lidocaine Condition
Performance on a short computer-based test of memory for visual pictures will be quantified using signal detection metric d-prime, reflecting ability (in standard deviation units) to detect previously-seen images from the background "noise" of previously un-seen images. Differences will be determined between the drug-free condition and the lidocaine condition. Higher values of d-prime indicate stronger memory performance; a positive difference for drug-free minus lidocaine condition would indicate the expected decrease in memory performance.
Time frame: 3 minutes
Motor Response Time Differences
Response times (in ms) after hearing a tone will be recorded and compared between the drug-free and Lidocaine condition, with the calculated difference in response times reported. Higher values will reflect slower responses, which are expected under the lidocaine condition.
Time frame: 1 minute
| Milestone | Lidocaine |
|---|---|
| Started | 30 |
| Completed | 27 |
| Not completed | 3 |
The Z-score is calculated by linear regression of the task timing against the MRI signal time-course (MRI data is in arbitrary units with no maximum or minimum) at each voxel (single data point in brain). Primary outcome is listed for the Right insula, but similar scores are calculated throughout the brain. Z-score of 0 indicates no task-related changes. Z-scores further from zero indicate stronger correlation between functional MRI signal change and the task timing, with positive values indicating increases in fMRI signal and negative Z-scores indicating decreases. Practically, higher positive Z-scores indicate increased brain activity and larger negative Z-scores indicate decreased brain activity. This outcome is reported as a number, as it is calculated using all the data across subjects combined into one statistical measure for the overall strength of difference in MRI signal change between two groups of data. Dispersion measures cannot be calculated for the summary Z-score.
| Z-score | Lidocaine |
|---|---|
| Brain Activation to Painful Stimulation Difference: Drug-free Condition Minus Lidocaine Condition | 3.6 |
Functional connectivity (FC) measures the correlation of MRI signal time-series between brain regions. Changes in FC reflect differences in brain state, in this case between drug-free and lidocaine conditions. The reported value is the FC change between the right insula and anterior cingulate. A T-statistic of 0 indicates no change; more positive scores mean stronger connectivity in the drug-free condition, and more negative scores mean stronger connectivity with lidocaine. This outcome is a number reflecting the overall magnitude of difference between two datasets, calculated in one summary statistic. Dispersion measures cannot be calculated for the T-statistic in this analysis framework.
| T-statistic | Lidocaine |
|---|---|
| Resting-state Functional Connectivity Difference: Drug-free Minus Lidocaine | 3.25 |
Numerical rating scale (0-10) pain score difference, comparing drug-free to the steady-state dose of lidocaine. Higher pain scores indicate more pain; a positive difference between pain score during the drug-free condition minus the value during the lidocaine condition indicates pain reduction (a better outcome).
| units on a scale | Lidocaine |
|---|---|
| Pain Intensity Score Difference, Drug-free Condition Minus Lidocaine Condition | 0.4 ± 0.2 |
Performance on a short computer-based test of memory for visual pictures will be quantified using signal detection metric d-prime, reflecting ability (in standard deviation units) to detect previously-seen images from the background "noise" of previously un-seen images. Differences will be determined between the drug-free condition and the lidocaine condition. Higher values of d-prime indicate stronger memory performance; a positive difference for drug-free minus lidocaine condition would indicate the expected decrease in memory performance.
| d-prime | Lidocaine |
|---|---|
| Memory Performance Difference, Drug-free Minus Lidocaine Condition | 0.48 (0.12 to 0.85) |
Response times (in ms) after hearing a tone will be recorded and compared between the drug-free and Lidocaine condition, with the calculated difference in response times reported. Higher values will reflect slower responses, which are expected under the lidocaine condition.
| milliseconds | Lidocaine |
|---|---|
| Motor Response Time Differences | 10 ± 100 |
Collected over 1 hour. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lidocaine | 0/27 (0%) | 0/27 (0%) | 0/27 (0%) |
Completed participants
| Age, Continuous(years) | Lidocaine |
|---|---|
| Mean | 31.4 ± 10.4 |
| Sex: Female, Male(Participants) | Lidocaine |
|---|---|
| Female | 14 |
| Male | 13 |
| Ethnicity (NIH/OMB)(Participants) | Lidocaine |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 20 |
| Unknown or Not Reported | 6 |
| Race (NIH/OMB)(Participants) | Lidocaine |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 14 |
| More than one race | 1 |
| Unknown or Not Reported | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2022 to primary completion in Nov 2023, 11 months.
Results were first posted in Dec 2024, 1 year 1 month after primary completion.
Of 118 non-industry phase 1 interventional studies under Pain, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 11 months is below that.
Counting every sponsor, half of 222 studies reached it within 9 months; a quarter within 3 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lidocaine
Keith M Vogt